This is a high-probability distress event with a very short timeline. The October 15, 2026 forbearance deadline creates a binary catalyst: either the company secures a rescue financing, strategic transaction, or extension, or it faces acceleration of all debt and likely bankruptcy. The $20M preferred stock issuance at a $1.62 conversion price (vs. current market) signals deep distress and will dilute common equity if converted. Monitor for any pre-market announcements regarding FDA acceptance of the sNDA for selinexor in myelofibrosis, which is a termination trigger if rejected, or any news of a capital raise or strategic alternative.
KPTI drugs
KPTI drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 11 $1.61entry
- T+1 · 2mo ago −0.62%α −0.17% · $1.60
- T+5 · 2mo ago +16.77%α +16.99% · $1.88
- T+20 · 6w ago −62.42%α −64.29% · $0.6050
- T+46 · todayOpen
- T+60 · in 20d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Karyopharm Therapeutics has entered into a forbearance agreement with 100% of its term loan lenders, convertible noteholders, and royalty investors, after failing to make a ~$15.8M principal payment due September 10, 2026, and not expecting to pay cash interest due September 30, 2026. The forbearance period runs to October 15, 2026, providing a short window to negotiate a restructuring, raise equity, or pursue strategic alternatives, but the company explicitly states that absent additional funding, it will be unable to continue as a going concern and may seek bankruptcy protection. As consideration, the company will issue $20M of convertible preferred stock (convertible at $1.62/share) to the consenting lenders, adding further dilution risk to common equity holders.
Key Financial Metrics
Key Facts
- Company did not pay ~$15.8M principal installment due September 10, 2026 under its Term Loan Credit Agreement.
- Company does not expect to pay cash interest due September 30, 2026 under the Credit Agreement and Indentures.
- Company did not make cash interest payments on the 2028 and 2029 Notes on June 30, 2026 (~$2.8M in unpaid interest).
- Forbearance period runs only until October 15, 2026, providing a very short runway.
- Company states that absent additional funding, it will be unable to continue as a going concern and may seek bankruptcy protection.
- Company will issue $20M of 0% convertible perpetual preferred stock (20,000 shares at $1,000/share, convertible at $1.62/share) as forbearance consideration to lenders.
- As of September 10, 2026, ~$129.0M of term loan principal, $15.6M of 2028 Notes, and $108.0M of 2029 Notes were outstanding.
- Future royalty obligations under the Royalty Agreement totaled $113.5M as of September 10, 2026.
- Company expects existing liquidity to fund operations only until October 15, 2026.
- Liquidity covenant under debt agreements requires $25M minimum after October 10, 2026, which the company may not satisfy.
Financial Impact
Company has ~$252.6M in total debt (term loan $129.0M, 2028 Notes $15.6M, 2029 Notes $108.0M) plus $113.5M in future royalty obligations. $20M in convertible preferred stock issued as forbearance fee. Cash runway only through October 15, 2026.
Risk Factors
- Forbearance period expires October 15, 2026, very limited time to restructure or raise capital.
- Any adverse FDA action on the sNDA for selinexor/myelofibrosis triggers immediate termination of forbearance.
- Consolidated liquidity falling below $10M triggers immediate termination of forbearance.
- If forbearance terminates, all overdue amounts become immediately due and payable in cash, likely forcing bankruptcy.
- $20M convertible preferred stock issuance at $1.62/share conversion price creates significant dilution risk for common shareholders.
- Company explicitly states it may be unable to continue as a going concern absent additional funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-388621 |
| Document: d94769dex102.htm | 0001193125-26-388621 |
| Document: d94769d8k.htm | 0001193125-26-388621 |
| Document: 0001193125-26-388621-index-headers.html | 0001193125-26-388621 |
| Document: 0001193125-26-388621-index.html | 0001193125-26-388621 |
| Document: 0001193125-26-388621.txt | 0001193125-26-388621 |
Track record
30 reports on KPTI
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +97.24% at T+60 after the Aug 13, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.0102 Now $0.0290 +184.31% settles Feb 12
- Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.0102 Now $0.0290 −184.31% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $0.0260 Now $0.0290 +11.54% settles Feb 10
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $0.0400 Now $0.0290 −27.50% settles Feb 5
- Nov 5, 202611d ago 8-K Bearish 8/10 Entry $0.0601 Now $0.0290 +51.75% settles Feb 3
- Nov 2, 202614d ago 8-K Bearish 10/10 Entry $0.0883 Now $0.0290 +67.16% settles Feb 1
- Nov 2, 202614d ago 8-K Bearish 7/10 Entry $0.1120 Now $0.0290 +74.11% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Bearish 5/10 Entry $0.8798 Now $0.0290 +96.70% settles Jan 27
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $0.5175 Now $0.0290 +94.40% settles Jan 21
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.3150 Now $0.0290 −90.79% settles Jan 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers